1
|
Valter K, Tedford SE, Eells JT, Tedford CE. Photobiomodulation use in ophthalmology - an overview of translational research from bench to bedside. FRONTIERS IN OPHTHALMOLOGY 2024; 4:1388602. [PMID: 39211002 PMCID: PMC11358123 DOI: 10.3389/fopht.2024.1388602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 02/20/2024] [Accepted: 07/04/2024] [Indexed: 09/04/2024]
Abstract
Photobiomodulation (PBM) refers to the process in which wavelengths of light are absorbed by intracellular photoacceptors, resulting in the activation of signaling pathways that culminate in biological changes within the cell. PBM is the result of low-intensity light-induced reactions in the cell in contrast to thermal photoablation produced by high-intensity lasers. PBM has been effectively used in the clinic to enhance wound healing and mitigate pain and inflammation in musculoskeletal conditions, sports injury, and dental applications for many decades. In the past 20 years, experimental evidence has shown the benefit of PBM in increasing numbers of retinal and ophthalmic conditions. More recently, preclinical findings in ocular models have been translated to the clinic with promising results. This review discusses the preclinical and clinical evidence of the effects of PBM in ophthalmology and provides recommendations of the clinical use of PBM in the management of ocular conditions.
Collapse
Affiliation(s)
- Krisztina Valter
- Clear Vision Laboratory, John Curtin School of Medical Research, Eccles Institute of Neuroscience, Canberra, ACT, Australia
- School of Medicine and Psychology, Australian National University, Canberra, ACT, Australia
| | | | - Janis T. Eells
- College of Health Professions and Sciences, University of Wisconsin-Milwaukee, Milwaukee, WI, United States
| | | |
Collapse
|
2
|
Liebert A, Bicknell B, Markman W, Kiat H. A Potential Role for Photobiomodulation Therapy in Disease Treatment and Prevention in the Era of COVID-19. Aging Dis 2020; 11:1352-1362. [PMID: 33269093 PMCID: PMC7673843 DOI: 10.14336/ad.2020.0901] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2020] [Accepted: 09/01/2020] [Indexed: 12/23/2022] Open
Abstract
COVID-19 is an evolving pandemic that has far reaching global effects, with a combination of factors that makes the virus difficult to contain. The symptoms of infection can be devastating or at the least very debilitating for vulnerable individuals. It is clear that the elderly are at most risk of the adverse impacts of the virus, including hospitalization and death. Others at risk are those with comorbidities such as cardiovascular disease and metabolic conditions and those with a hyper-excitable immune response. Treatment options for those with acute responses to the virus are limited and there is an urgent need for potential strategies that can mitigate these severe effects. One potential avenue for treatment that has not been explored is the microbiome gut/lung axis. In addition to those severely affected by their acute reaction to the virus, there is also a need for treatment options for those that are slow to recover from the effects of the infection and also those who have been adversely affected by the measures put in place to arrest the spread of the virus. One potential treatment option is photobiomodulation (PBM) therapy. PBM has been shown over many years to be a safe, effective, non-invasive and easily deployed adjunctive treatment option for inflammatory conditions, pain, tissue healing and cellular energy. We have also recently demonstrated the effectiveness of PBM to alter the gut microbiome. PBM therapy is worthy of consideration as a potential treatment for those most vulnerable to COVID-19, such as the elderly and those with comorbidities. The treatment may potentially be advantageous for those infected with the virus, those who have a slow recovery from the effects of the virus and those who have been denied their normal exercise/rehabilitation programs due to the isolation restrictions that have been imposed to control the COVID-19 pandemic.
Collapse
Affiliation(s)
- Ann Liebert
- Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
- Research and Governance, Adventist Hospital Group, Wahroonga, Australia.
- SYMBYX Pty Ltd, Artarmon, Australia.
| | - Brian Bicknell
- SYMBYX Pty Ltd, Artarmon, Australia.
- Faculty of Health Science, Australian Catholic University, North Sydney, Australia.
| | - Wayne Markman
- SYMBYX Pty Ltd, Artarmon, Australia.
- School of Business, University of Technology, Sydney, Australia.
| | - Hosen Kiat
- Cardiac Health Institute, Sydney, Australia.
- Faculty of Medicine, University of NSW, Kensington, Australia.
- Faculty of Medicine, health and Human Sciences, Macquarie University, Macquarie Park, Australia
| |
Collapse
|
3
|
Kent AL, Abdel-Latif ME, Cochrane T, Broom M, Dahlstrom JE, Essex RW, Shadbolt B, Natoli R. A pilot randomised clinical trial of 670 nm red light for reducing retinopathy of prematurity. Pediatr Res 2020; 87:131-136. [PMID: 31430763 DOI: 10.1038/s41390-019-0520-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/11/2019] [Revised: 07/03/2019] [Accepted: 07/10/2019] [Indexed: 11/09/2022]
Abstract
BACKGROUND Photobiomodulation by 670 nm red light in animal models reduced severity of ROP and improved survival. This pilot randomised controlled trial aimed to provide data on 670 nm red light exposure for prevention of ROP and survival for a larger randomised trial. METHODS Neonates <30 weeks gestation or <1150 g at birth were randomised to receive 670 nm for 15 min (9 J/cm2) daily until 34 weeks corrected age. DATA COLLECTED placental pathology, growth, days of respiratory support and oxygen, bronchopulmonary dysplasia, patent ductus arteriosus, necrotising enterocolitis, sepsis, worst stage of ROP, need for laser treatment, and survival. RESULTS Eighty-six neonates enrolled-45 no red light; 41 red light. There was no difference in severity of ROP (<27 weeks-p = 0.463; ≥27 weeks-p = 0.558) or requirement for laser treatment (<27 weeks-p = 1.00; ≥27 weeks-no laser treatment in either group). Survival in 670 nm red light treatment group was 100% (41/41) vs 89% (40/45) in untreated infants (p = 0.057). CONCLUSION Randomisation to receive 670 nm red light within 24-48 h after birth is feasible. Although no improvement in ROP or survivability was observed, further testing into the dosage and delivery for this potential therapy are required.
Collapse
Affiliation(s)
- Alison L Kent
- Division of Neonatology, Golisano Children's Hospital, University of Rochester, Rochester, NY, USA. .,Australian National University Medical School, Canberra, ACT, 2601, Australia.
| | - Mohamed E Abdel-Latif
- Australian National University Medical School, Canberra, ACT, 2601, Australia.,Department of Neonatology, Centenary Hospital for Women and Children, Canberra Hospital, Woden, ACT, 2606, Australia
| | - Timothy Cochrane
- Australian National University Medical School, Canberra, ACT, 2601, Australia.,Department of Neonatology, Centenary Hospital for Women and Children, Canberra Hospital, Woden, ACT, 2606, Australia
| | - Margaret Broom
- Department of Neonatology, Centenary Hospital for Women and Children, Canberra Hospital, Woden, ACT, 2606, Australia
| | - Jane E Dahlstrom
- Australian National University Medical School, Canberra, ACT, 2601, Australia.,Department of Anatomical Pathology, Canberra Hospital, Woden, ACT, 2606, Australia.,John Curtin School of Medical Research, College of Medicine Biology and Environment, ANU, Canberra, ACT, 2601, Australia
| | - Rohan W Essex
- Australian National University Medical School, Canberra, ACT, 2601, Australia.,Department of Ophthalmology, Canberra Hospital, Woden, ACT, 2606, Australia
| | - Bruce Shadbolt
- Australian National University Medical School, Canberra, ACT, 2601, Australia.,Clinical Epidemiology, Canberra Hospital, Woden, ACT, 2606, Australia
| | - Riccardo Natoli
- Australian National University Medical School, Canberra, ACT, 2601, Australia.,John Curtin School of Medical Research, College of Medicine Biology and Environment, ANU, Canberra, ACT, 2601, Australia
| |
Collapse
|